Target intelligence / Profile preview

Synemin antisense RNA 1 (SYNM-AS1)

Target
SYNM-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Non-coding RNA
01

Overview

Synemin antisense RNA 1 (SYNM-AS1) is a long non-coding RNA (lncRNA) transcribed from the strand of DNA opposite the SYNM gene locus. As a **natural antisense transcript (NAT)**, its RNA is complementary to the SYNM mRNA, potentially enabling it to regulate SYNM gene expression either through direct base-pairing interactions or by influencing chromatin and transcriptional dynamics. NATs, including SYNM-AS1, are increasingly recognized as important regulators of gene expression at multiple levels, potentially impacting chromatin structure, transcription, and translation. While many NATs play roles in disease, especially cancer and epigenetic disorders, there is no published evidence directly linking SYNM-AS1 to disease or drug interactions at this time.

Other names
SYNM-AS1Synemin antisense RNA 1SYNM antisense transcript 1
02

Mechanism of action

Not applicable (for drugs targeting SYNM-AS1; general mechanisms of antisense RNAs include blocking mRNA translation, recruiting RNA-modifying proteins, or affecting chromatin state)

03

Biological functions

Gene expression regulationEpigenetic regulationOther (Specific biological function for SYNM-AS1 is not described in available sources; functions are inferred from the role of antisense RNAs and NATs generally)
04

Disease associations

Other (no direct evidence of involvement in specific diseases for SYNM-AS1; generally, NATs can participate in cancer, genetic diseases, and epigenetic regulation, but no specific disease role is documented for SYNM-AS1)
05

Safety considerations

None specific (General concerns with targeting lncRNAs/NATs in therapy include off-target effects, delivery, and immune response, but no safety data for SYNM-AS1 specifically)
06

Interacting drugs

None known (as of current literature and databases; antisense or RNA-targeting drugs are being developed in the field, but no drug is listed as directly targeting SYNM-AS1)
07

Biomarkers

None known (SYNM-AS1 is not reported as a biomarker for patient selection or efficacy monitoring in current sources)

Beyond the preview

Go deeper on Synemin antisense RNA 1 (SYNM-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synemin antisense RNA 1 (SYNM-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call